Health
Genentech Announces FDA Approval of Xofluza for the Prevention of Influenza Following Contact With an Infected Person – Business Wire
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved a s
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Xofluza® (baloxavir marboxil) as a treatment to prevent influenza in people 12 years of age and older following contact with someone with influenza (known as post-exposure prophylaxis). Xofluza is the first single-dose influenza medicine approved for post-exposure…
-
Noosa News17 hours agoCommissioner thanks police officer who threw a speed radar at a car
-
Noosa News22 hours agoBrisbane news live: Federal fund for council’s cyclone clean-up dries up
-
Noosa News15 hours agoNo matter what happens in his Origin debut, history beckons for rookie maroon Robert Toia
-
Noosa News16 hours agoGood character references restricted in rape cases in Queensland